Most Liquid Pharmaceutical Products Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1LSBPW LakeShore Biopharma Co,
255.6 M
(0.06)
 11.52 
(0.75)
2DNTH Dianthus Therapeutics
138.94 M
(0.10)
 3.82 
(0.37)
3VRTX Vertex Pharmaceuticals
9.77 B
(0.05)
 1.72 
(0.09)
4DNLI Denali Therapeutics
1.07 B
 0.00 
 3.41 
 0.00 
5VTRS Viatris
741.9 M
 0.10 
 2.26 
 0.22 
6DVAX Dynavax Technologies
518.17 M
 0.07 
 2.46 
 0.16 
7ELAN Elanco Animal Health
463 M
(0.04)
 2.57 
(0.09)
8EDIT Editas Medicine
452.56 M
(0.16)
 4.12 
(0.64)
9VNDA Vanda Pharmaceuticals
440.86 M
(0.03)
 2.60 
(0.08)
10ME 23Andme Holding Co
410.89 M
(0.15)
 6.51 
(0.95)
11DSGN Design Therapeutics
359.38 M
 0.04 
 5.62 
 0.23 
12VALN Valneva SE ADR
336.22 M
(0.35)
 2.48 
(0.87)
13VERV Verve Therapeutics
293.56 M
 0.01 
 4.56 
 0.02 
14VTYX Ventyx Biosciences
250.45 M
(0.09)
 3.69 
(0.32)
15DTIL Precision BioSciences
184.14 M
(0.13)
 3.25 
(0.43)
16VKTX Viking Therapeutics
155.02 M
(0.04)
 5.11 
(0.21)
17VIGL Vigil Neuroscience
148.91 M
(0.02)
 3.69 
(0.07)
18VYGR Voyager Therapeutics
148.06 M
(0.04)
 4.92 
(0.18)
19VERA Vera Therapeutics
131.93 M
 0.11 
 3.79 
 0.41 
20VXRT Vaxart Inc
129.55 M
(0.15)
 3.53 
(0.53)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).